Vodafone’s German operations have returned to growth after a previous decline, with service revenues increasing by approximately two percent to €2.74 billion. The company anticipates a strong overall performance for the fiscal year 2026/2027. In contrast, AstraZeneca reported a surprising 18 percent rise in adjusted earnings per share to $2.63, surpassing analyst expectations of $2.48, driven by robust sales of cancer and rare disease medications. The company reaffirmed its 2026 profit forecast, projecting a low double-digit percentage increase in adjusted earnings per share.